<DOC>
	<DOCNO>NCT00727194</DOCNO>
	<brief_summary>The purpose study determine whether eculizumab safe effective treatment patient generalize myasthenia gravis despite treatment various immunosuppressant , prednisone , methotrexate , Cellcept , cyclosporine , cyclophosphamide , currently available .</brief_summary>
	<brief_title>Safety Efficacy Study Eculizumab Patients With Refractory Generalized Myasthenia Gravis</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>Generalized MG MGFA Clinical Classification Class II , III IVa . QMG total score ≥12 Minimum score two ( 2 ) four ( 4 ) test item QMG Able give inform consent . Have fail least two immunosuppressant one year treatment A positive serologic test binding antiacetylcholine receptor Abs Screening one follow ) history abnormal neuromuscular transmission test demonstrate singlefiber electromyography repetitive nerve stimulation , b ) history positive anticholinesterase test , eg , edrophonium chloride test , c ) patient demonstrate improvement MG sign acetylcholinesterase inhibitor assess treat physician . History thymoma neoplasm thymus . History thymectomy within 12 month prior screen . Pregnancy lactation Current chronic use plasmapheresis/plasma exchange IVIG treatment within 8 week prior screen . Use etanercept within 2 month prior screen . Use rituximab ( RITUXAN® ) within 6 month prior screen . MGFA Class I , IVb , V Crisis impend crisis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>